Yumi Kotoda

Chuo, 4093821, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Genetic factors associated with response to as-needed brolucizumab treatment for exudative age-related macular degeneration.

Genetic factors associated with response to as-needed brolucizumab treatment for exudative age-related macular degeneration.

Journal: Japanese journal of ophthalmology
Published: January 16, 2026

Comparison of Three Consecutive Monthly Administrations Between Aflibercept 8 mg and Brolucizumab 6 mg in Polypoidal Choroidal Vasculopathy.

Comparison of Three Consecutive Monthly Administrations Between Aflibercept 8 mg and Brolucizumab 6 mg in Polypoidal Choroidal Vasculopathy.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: November 02, 2025

Recurrence of Intraocular Inflammation Following an Aflibercept 8-mg Injection in Eyes With a History of Intraocular Inflammation From Faricimab: A Case Report.

Recurrence of Intraocular Inflammation Following an Aflibercept 8-mg Injection in Eyes With a History of Intraocular Inflammation From Faricimab: A Case Report.

Journal: Cureus
Published: June 15, 2025

Genetic Factors Associated with Intraocular Inflammation After Brolucizumab Administration in Patients with Exudative Age-Related Macular Degeneration.

Genetic Factors Associated with Intraocular Inflammation After Brolucizumab Administration in Patients with Exudative Age-Related Macular Degeneration.

Journal: Genes
Published: June 08, 2025

Two year outcomes of as needed brolucizumab therapy in exudative age related macular degeneration with or without pachychoroid phenotype.

Two year outcomes of as needed brolucizumab therapy in exudative age related macular degeneration with or without pachychoroid phenotype.

Journal: Scientific reports
Published: March 24, 2025

Brolucizumab versus aflibercept in treating exudative age-related macular degeneration: a 12-month pro re nata regimen.

Brolucizumab versus aflibercept in treating exudative age-related macular degeneration: a 12-month pro re nata regimen.

Journal: Scientific reports
Published: March 03, 2025

Short-Term Outcomes of Three Consecutive Monthly Loading Administrations of Aflibercept 8 Mg for Treatment-Naïve Exudative Age-Related Macular Degeneration.

Short-Term Outcomes of Three Consecutive Monthly Loading Administrations of Aflibercept 8 Mg for Treatment-Naïve Exudative Age-Related Macular Degeneration.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: February 16, 2025

Clinical and genetic characteristics of simple central serous chorioretinopathy according to age.

Clinical and genetic characteristics of simple central serous chorioretinopathy according to age.

Journal: Ophthalmic genetics
Published: November 11, 2024

A Novel Quaternary Ammonium N-Propylamiodarone Bromide Provides Long-Lasting Analgesia Against Corneal Pain.

A Novel Quaternary Ammonium N-Propylamiodarone Bromide Provides Long-Lasting Analgesia Against Corneal Pain.

Journal: Drug design, development and therapy
Published: September 03, 2024

Association of Polyp Regression after Loading Phase with 12-Month Outcomes of Eyes with Polypoidal Choroidal Vasculopathy.

Association of Polyp Regression after Loading Phase with 12-Month Outcomes of Eyes with Polypoidal Choroidal Vasculopathy.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: May 03, 2024

Genetic and Clinical Characteristics of Central Serous Chorioretinopathy With Steroid Use.

Genetic and Clinical Characteristics of Central Serous Chorioretinopathy With Steroid Use.

Journal: Cureus
Published: April 20, 2024

INCIDENCE AND CHARACTERISTICS OF NEOVASCULAR AGE-RELATED MACULAR WITH OVER A 12-MONTH REMISSION AFTER THREE MONTHLY AFLIBERCEPT ADMINISTRATION: 60 Months Results of a Pro Re Nata Regimen.

INCIDENCE AND CHARACTERISTICS OF NEOVASCULAR AGE-RELATED MACULAR WITH OVER A 12-MONTH REMISSION AFTER THREE MONTHLY AFLIBERCEPT ADMINISTRATION: 60 Months Results of a Pro Re Nata Regimen.

Journal: Retina (Philadelphia, Pa.)
Published: February 20, 2024
Showing 1-12 of 21

Last Updated: 09/26/2026